NEWS
< back to news list

CET’s acquisition of NanoSanguis S.A. shares.

In December 2023, we informed about concluding an advisory agreement with CET Advisors LTD in the commercialization process of projects conducted by NanoSanguis S.A. (hereinafter also referred to as the “Company”). On Friday, June 21, 2024, CET concluded an agreement with the Company to acquire 100,000 shares of Nanosanguis S.A. This is also the fulfillment of the provisions of the agreement concluded in December last year. Thus, CET becomes a shareholder of NanoSanguis S.A.

At the same time, based on the agreement concluded with CET in December 2023, he is entitled to apply to NanoSanguis S.A. with a request to convert the purchased 100,000 shares of the Company into shares of Nanogroup S.A. in the ratio of 613 shares of Nanogroup S.A. for each 100 shares of NanoSanguis S.A. held by CET. Management Board of NanoSanguis S.A. has undertaken to perform all activities enabling such conversion. To carry it out, the consent of the governing bodies of NanoGroup S.A. is required, including a resolution of the general meeting. The shares of NanoGroup S.A. obtained by CET as a result of the conversion. will be subject to a 12-month sales ban from the date of their acquisition by CET.

CET is part of the Clairfield International SA group based in Geneva and as a group provides advisory services in the field of sale and purchase of enterprises as well as mergers and acquisitions. The group has extensive experience in transactions with companies from the medical technology and biotechnology industries, with successes in the global commercialization of products from the Polish biotechnology market.

We are glad that such a renowned transaction advisor believes in the project and the possibility of achieving great success by NanoSanguis S.A.

Copyright © NanoGroup 2024

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.